Published in the Journal of Advanced Therapeutic Science, the Pr2—or prion-priion—theory reframes amyloid and tau proteins as remnants of an ancient protective mechanism. In this model, these proteins serve as a defense against threats like chronic infection, toxins, and metabolic stress. When these threats persist, the protective response shifts into a state of damaging inflammation, eventually leading to the loss of neural function. This perspective explains why some individuals remain cognitively healthy despite significant amyloid accumulation, as their neural networks may not yet have succumbed to the sustained stress that triggers pathology.

Bredesen suggests that neurodegenerative disorders such as Parkinson’s and ALS reflect vulnerabilities in specific neural networks, influenced by factors ranging from sleep apnea to air pollution. This shift in focus moves the medical goalposts toward precision medicine, where practitioners identify and mitigate a patient’s unique combination of triggers rather than targeting a single protein. While early proof-of-concept studies have shown promise in stabilizing cognitive health, the author stresses that broader clinical testing is required to validate this multi-factor approach. By moving beyond the simple goal of clearing pathology, the model asks clinicians to restore the specific conditions required for healthy neural function.